Aggressive MS

THURSDAY, 1 MARCH 2018

08.30 - 08.45  Welcome from ECTRIMS president
   D. Miller (London, UK)

08.45 - 09.45  Session 1: How to define aggressive MS
   Chairs: H. Tremlett (Vancouver, CA), M. S. Freedman (Ottawa, CA)
   Definition of aggressive MS

08.45  At disease onset: bad relapse versus bad outcome
   L. Brundin (Stockholm, SE)

09.05  In treated patients with relapsing and progressive MS
   E. Havrdová (Prague, CZ)

09.35 – 10.05  Roundtable/Panel discussion 1: Consensus/controversies on aggressive MS definition
   Panel members: H. Tremlett (Vancouver, CA), M. S. Freedman (Ottawa, CA),
   L. Brundin (Stockholm, SE), E. Havrdová (Prague, CZ),
   X. Montalban (Barcelona, ES)

10.05 – 10.35  Coffee break

10.35 – 11.35  Session 1: How to define aggressive MS (continued)
   Chairs: H. Tremlett (Vancouver, CA), M. S. Freedman (Ottawa, CA)
   Epidemiology and pathophysiology of aggressive MS

10.35  Regional differences
   H.J. Kim (Seoul, KR)

10.55  Pathology
   B. Trapp (Cleveland, US)

11.15  Immunology
   R. Liblau (Toulouse, FR)
11.35 – 12.15  Session 2: Can we predict aggressive MS: lessons from real world data
Chairs: M. Trojano (Bari, IT), J. Hillert (Stockholm, SE)

11.35  Long term cohorts
*M. Tintore (Barcelona, ES)*

11.55  Registries
*T. Kalincik (Melbourne, AU)*

12.15 - 13.00  Roundtable/Panel discussion 2: Is modelling the course and outcomes of MS feasible?
*Panel members: M. Trojano (Bari, IT), J. Hillert (Stockholm, SE), M. Tintore (Barcelona, ES), T. Kalincik (Melbourne, AU)*

13.00 - 14.00  Lunch break

14.00 - 16.00  Session 3: How to manage aggressive MS
Chairs: H.P. Hartung (Düsseldorf, DE), M. P. Amato (Florence, IT)

14.00  How to communicate aggressive MS: which are the limits and the range of error: counselling in delivering bad news
*A. Solari (Milan, IT)*

14.20  Treatment of severe relapses
*R. Gold (Bochum, DE)*

14.40  Is there a place for orals?
*S. Vukusic (Lyon, FR)*

15.00  Is there a place for Monoclonal Abs
*B. Hemmer (Munich, DE)*

15.20  Is there a place for BMT
*P. Muraro (London, UK)*

15.40  Management of aggressive, progressive MS  (*via video conference*)
X. Montalban (Toronto, CA)

16.00 - 16.30  Coffee break
**16.30 – 17.30**  
**Session 3: How to manage aggressive MS (continued)**  
Chairs: H.P. Hartung (Düsseldorf, DE), M. P. Amato (Florence, IT)

16.30  
**Out boundaries: How would you treat aggressive MS**  
*K. Schmierer (London, UK)*

16.50  
**Specific situations in pregnancy**  
*K. Hellwig (Bochum, DE)*

17.10  
**Specific situations in children**  
*E. Waubant (San Francisco, US)*

17.30  
**Specific situations in senior patients – using population-based data to highlight opportunity and need**  
*H. Tremlett (Vancouver, CA)*

**17.50 - 18.20**  
**Roundtable/Panel discussion 3: Treatments strategies**  
*Panel members: H.P. Hartung (Düsseldorf, DE) M. P. Amato (Florence, IT), A. Solari (Milan, IT), R. Gold (Bochum, DE), S. Vukusic (Lyon, FR), B. Hemmer (Munich, DE), P. Muraro (London, UK), K. Schmierer (London, UK), K. Hellwig (Bochum, DE), E. Waubant (San Francisco, US), H. Tremlett (Vancouver, CA)*

**18.20 - 18.30**  
**Wrap-up day 1**  
*L. Brundin (Stockholm, SE)*

**19.30**  
**Workshop Dinner**

**FRIDAY, 2 March 2018**

**08.30 - 09.50**  
**Session 4: How to make progress in aggressive MS**  
Chairs: A. Thompson (London, UK), L. Kappos (Basel, CH)

08.30  
**MRI contribution**  
*O. Ciccarelli (London, UK)*

08.50  
**Biomarkers contribution**  
*T. Derfuss (Basel, CH)*

09.10  
**New trial design**  
*G. Cutter (Birmingham, UK)*
09.30       New drugs
             L. Kappos (Basel, CH)

09.50 - 10.30  Roundtable/Panel discussion 4: Moving forward
               Panel members: A. Thompson (London, UK), T. Derfuss (Basel, CH),
               G. Cutter (Birmingham, UK), O. Ciccarelli (London, UK), L. Kappos (Basel,
               CH)

10.30 - 11.00  Coffee break

11.00 - 12.00  Session 5: How to manage and prevent complications of high efficacy
               treatments
               Chairs: R. Gold (Bochum, DE), P. Soelberg Sørensen (Copenhagen, DK)

               Infectious risk in patients with biologicals or other immunosuppressive
               drugs

11.00         PML
              J. Berger (Philadelphia, US)

11.20         Cancer, Papiloma V, listeria and other infections
              A.J. Coles (Cambridge, UK)

               Preventive strategies: Treatment of latent / pre-existing infections

11.40         Vaccination: which and when and travel advise
              J. L. Fredriksen (Copenhagen, DK)

12.00 - 12.45  Roundtable/Panel discussion 5: Complications management and
               preventive strategies
               Panel members: R. Gold (Bochum, DE), P. Soelberg Sørensen (Copenhagen,
               (Copenhagen, DK)

12.45 - 13.45  Lunch break

13.45 - 14.45  Meeting Summary
               M. Tintore (Barcelona, ES), B. Hemmer (Munich, DE)